https://www.aigom.it/wp-content/uploads/2026/07/art14.7-copertina.png692450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-14 16:21:302026-07-14 16:21:30PREDICTING THE PROGNOSIS OF BREAST CANCER BY USING NUTRION-BASED INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS.
https://www.aigom.it/wp-content/uploads/2026/07/art7.7.png651400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-07 07:43:362026-07-07 07:43:36DEFINING CARDIOVASCULAR ENDPOINTS IN ONCOLOGY TRIALS: CHALLENGES AND OPPORTUNITIES: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION.
https://www.aigom.it/wp-content/uploads/2026/06/ART30.6.png645450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-30 13:51:182026-06-30 13:51:18OPPORTUNISTIC SALPINGECTOMY FOR PREVENTION OF TUBO-OVARIAN CARCINOMA: THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY CONSENSUS STATEMENTS.
https://www.aigom.it/wp-content/uploads/2026/06/ART23.1.png714450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-23 06:35:132026-06-23 06:35:13THE PATHOLOGIC RESPONSE EVALUATION AND DETECTION IN CIRCULATING TUMOR-DNA STUDY: ULTRASENSITIVE CIRCULATING TUMOR-DNA ASSESSMENT OF BREAST CANCER MINIMAL RESIDUAL DISEASE.
https://www.aigom.it/wp-content/uploads/2026/06/ART9.6.png501400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-09 09:50:562026-06-09 09:50:56FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
https://www.aigom.it/wp-content/uploads/2026/05/ART26.5-1.png431400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-26 08:14:012026-05-26 08:15:37PREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-19-095945-Copia.png480600Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-19 08:01:482026-05-19 08:01:48ERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-12-122913.png633400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-12 10:31:232026-05-12 10:31:23RISK OF BREAST CANCER AFTER OVARIAN CANCER IN WOMEN WITH A PATHOGENIC/LIKELY PATHOGENIC VARIANT IN BRCA1 OR BRCA2.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-05-104358.png400311Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-05 08:28:522026-05-05 08:49:21PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2026/04/Screenshot-2026-04-21-104313.png448400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-21 08:45:252026-05-05 08:59:07ADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL.
